VivoSeq
Oncology

Triple-Negative Breast Cancer

200

Pipeline Programs↗

111

Active Trials↗

73

Companies Involved↗

Triple-Negative Breast Cancer is a highly competitive landscape with 200 programs across 73 companies. The most active players are Arcus Biosciences, Eastern Cooperative Oncology Group, Infinity Pharmaceuticals, Inc.. 10 therapies are approved with 45 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

83/100

Pipeline Velocity

58/100

Mech. Concentration

7/100

Completion Rate

61/100

Attrition Rate

12/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Arcus Biosciences logo

Arcus Biosciences

2 programs

Phase 1E

Eastern Cooperative Oncology Group

2 programs

Phase 1I

Infinity Pharmaceuticals, Inc.

1 program

Phase 1C

Celldex Therapeutics

1 program

Phase 1H

Hoffman Oncology

1 program

Phase 1Taiho Oncology, Inc. logo

Taiho Oncology, Inc.

1 program

Phase 1

Pipeline

Programs by Phase

Preclinical9

Atezolizumab

Roche

Zoledronic Acid

Pfizer

PD-1 Inhibitor

Johnson & Johnson

Adjuvant Chemotherapy

Nizhny Novgorod Regional Clinical Oncology Center

Vorinostat

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 132

Celecoxib

Philadelphia Eye Associates

Adavosertib

AstraZeneca

Lenvatinib

Eisai

Nivolumab

Bristol-Myers Squibb

Durvalumab

AstraZeneca

Phase 2104

Talazoparib

Pfizer

Sargramostim

Sanofi

Olaparib

AstraZeneca

Abemaciclib

Eli Lilly

Ivonescimab

Summit Therapeutics

Phase 345

Cisplatin

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Eribulin Mesylate

Eisai

Toripalimab

Coherus Oncology, Inc.

Gemcitabine

Johnson & Johnson

Carboplatin

Avyxa

Approved10

Capivasertib

AstraZeneca

Ivermectin

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Metformin

EMD Serono

Lobaplatin

Sun Yat-sen University

Huaier Granule

Qidong Gaitianli Medicines Co., Ltd

Analysis

Modality Breakdown

80%

Small molecule

188 of 235 classified programs — the dominant modality here.

20%ALL OTHERSMonoclonal antibody3214%Vaccine73%Antibody–drug conjugate42%Protein / enzyme31%Cell therapy1<1%

Small molecule leads; the ring shows all 235 classified programs, each share of the total. Modality classified for 97% of 250 pipeline programs.

Analysis

Trial Status

218

clinical trials

Recruiting47 · 22%
Completed43 · 20%
Unknown status36 · 17%
Not yet recruiting33 · 15%
Active, not recruiting31 · 14%
Terminated15 · 7%
Other13 · 6%

Clinical Trials

Trial Activity

218 trials

Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic Triple-negative Breast Cancer
Recruiting·SSun Yat-Sen University Cancer Center·Phase 3·NCT04722978·228 enrolled
Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer
Recruiting·SStanford University·Phase 2·NCT04768426·40 enrolled
Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer
Recruiting·FFudan University·Phase 4·NCT04790305·1,072 enrolled
A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer
Recruiting·SSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.·Phase 3·NCT06279364·524 enrolled
Neoadjuvant Toripalimab Plus SBRT for Chemo-Resistant Triple-Negative Breast Cancer
Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT07457359·18 enrolled
A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer
Recruiting·MMabwell (Shanghai) Bioscience Co., Ltd.·Phase 2·NCT06492005·160 enrolled
A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer
Recruiting·Suzhou Suncadia Biopharmaceuticals Co., Ltd. logoSuzhou Suncadia Biopharmaceuticals Co., Ltd.·Phase 3·NCT07111832·400 enrolled
A Prospective, Open-label, Single-arm, Exploratory Clinical Trial to Evaluate the Safety and Tolerability of 225Ac-TR2205 Injection in Patients With Triple-negative Breast Cancer.
Recruiting·—·Phase 1·NCT07340424·15 enrolled
The Clinical Study of the Efficacy and Safety of Trop2-ADC Monotherapy or Combination Immunotherapy Strategy in the Treatment of Advanced Triple-negative Breast Cancer.
Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT06851299·60 enrolled
Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer
Recruiting·QQueen Mary University of London·Phase 2·NCT06954480·140 enrolled
OPTImaL:Optimisation of Treatment for Patients With Low Stage Triple-negative Breast Cancer With High Stromal Tumor-infiltrating Lymphocytes
Recruiting·TThe Netherlands Cancer Institute·N/A·NCT06476119·490 enrolled
Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
Recruiting·National Cancer Institute (NCI)·Phase 1·NCT05422794·57 enrolled
Arsenous Acid for Refractory Triple-Negative Breast Cancer
Recruiting·SSun Yat-sen University·Phase 2·NCT06678048·12 enrolled
Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC)
Recruiting·UUniversity of Illinois at Chicago·Phase 1·NCT04427293·12 enrolled
SBRT, Chemotherapy, and AK104 Neoadjuvant Therapy for Triple-negative Breast Cancer (TNBC)
Recruiting·—·Phase 2·NCT06401005·51 enrolled
Page 1 of 15

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)